Primary Samples and Relationship to Initial PGC Studies

Supplementary Information

Primary samples and relationship to initial PGC studies

Of the 39,202 samples included in this study (9,369 SCZ cases, 10,410 BP cases, 19,423 controls) 30,175 were included in the initial PGC studies of BP and SCZ (Supplementary Table 1). The additional samples new to this study came from 3 BP studies; 1) A French study of 451 BP cases and 1,631 controls, 2) the Swedish sample from the International Cohort Collection for Bipolar Disorder (ICCBD) for 824 BP cases and 2,084 controls and 3) an additional 401 BP cases and 171 controls from the Thematically Organized Psychosis Study. As well as BP samples collected as part of FaST STEP 2 which included 1,860 BP cases. To create a well powered US sample these 1,860 BP cases were combined with 674 BP cases from the GAIN/BIGS study and compared to 1,605 controls from the MIGen consortium. Overlapping individuals were identified (See Methods) across samples and were distributed randomly to the appropriate study in order to reach an ideal 1 control for every case. Supplementary Table 1 presents the samples used in the original PGC studies compared to this study after removing overlapping individuals.

Supplementary Table 1: Description of samples relation to previous PGC samples. (*indicates BP samples were combined into a single US based case samples and combined with MIGen controls) Previous PGC This PGC Study Study PGC SCZ Country Platform SCZ SCZ* Controls* Cardiff UK UK Affymetrix 500K 472 464 1527 Affymetrix 500K; CATIE United States 402 403 168 Perlegen 164K ISC-Aberdeen UK Affymetrix 5.0 720 718 698 ISC-Cardiff Bulgaria Affymetrix 6.0 527 527 609 ISC-Dublin Ireland Affymetrix 6.0 270 270 474 ISC-Edinburgh UK Affymetrix 6.0 368 365 153 Affymetrix 5.0; ISC-London UK 518 520 249 Affymetrix 500K ISC-Portugal Portugal Affymetrix 5.0 346 346 216 ISC-SW1 Sweden Affymetrix 500K 168 168 167 ISC-SW2 Sweden Affymetrix 6.0 390 388 229 United States, MGS Affymetrix 6.0 2679 2670 1834 Australia SGENE-Bonn Germany Illumina 550K 474 474 651 Illumina Human 610- SGENE-Copenhagen Denmark 482 483 457 Quad SGENE-Munich Germany Illumina 300K 434 433 351 SGENE-TOP3 Norway Affymetrix 6.0 248 245 120 SGENE-UCLA The Netherlands Illumina 550K 704 704 630 Zucker Hillside United States Affymetrix 500K 192 191 190 Total 9394 9369 8723

PGC BP BP BP* Controls* BOMA-Bipolar Study, University of Bonn and CIMH German Illumina 550 675 673 661 Mannheim Genetic Association Information Network (GAIN) / European- Affymetrix 6.0 542 674* 0 Bipolar Genome Study (BiGS) American British, Canadian GlaxoSmithKline (GSK) Illumina 550 890 737 903 or Scottish Pritzker Neuropsychiatric Disorders Research European- Illumina 550 1130 492 294 Consortium American Systematic Treatment Enhancement Program for European- Affymetrix 500K 922 917 915 Bipolar Disorder (STEP1) American Systematic Treatment Enhancement Program for European- Affymetrix 5.0 659 654 114 Bipolar Disorder (STEP2) American Thematically Organized Psychosis (TOP3) Study Norwegian Affymetrix 6.0 203 118 119 Trinity College Dublin Irish Affymetrix 6.0 150 150 406 University College London (UCL) British Affymetrix 500K 457 465 249 University of Edinburgh Scottish Affymetrix 6.0 282 279 140 Wellcome Trust Case-Control Consortium (WTCCC) British Affymetrix 500K 1571 1715 1408 748 PGC Samples Total 6874 5209 1

Additional BP Samples French France Illumina 650 451 1631

FaST STEP2 / Translational Genomics Institute 1 US Affymetrix 6.0 1860* 1605 (TGEN) International Cohort Collection for Bipolar Sweden Affymetrix 6.0 824 2084 Disorder (ICCBD) Sweden Thematically Organized Psychoses (TOP7) Norway Affymetrix 6.0 401 171 Additional Samples Total 3536 5491 Total 10410 10700 Case only (BP vs SCZ) samples

Supplementary Table 2. Independent sample groups for BP vs SCZ analysis Populatio n BP Samples SCZ Samples BP SCZ US1 GAIN, FaST STEP 2 MGS 2916 2674 US2 STEP1, STEP2 CATIE 1573 400 Sweden ICCBD-Sweden ISC-SW1, ISC-SW2 824 557 Norway TOP SGENE-TOP3 518 246 Germany BOMA SGENE-Bonn, SGENE-Munich 673 907 Ireland Dublin ISC-Dublin 150 270 Scotland University of Edinburgh ISC-Aberdeen, ISC-Edinburgh 280 1086 UK1 University College London (UCL) ISC-London 482 518 UK2 WTCCC Cardiff UK 1836 471 9,25 Total 2 7,129 In order to perform a well powered case only (BP vs SCZ) analysis we combined smaller samples by ancestral population and array technology to create 9 samples that had sufficient BP and SCZ samples. Further details on the six genome-wide significant hits

This table provides details on the six most significant SNPs within genomic regions reaching genome-wide significance (p- value > 5x10-8) in the BP+SCZ vs controls GWAS. Odds ratios (OR) and minor allele frequencies (MAF) are provided for both the combined phenotype test and each disease vs controls separately for comparison. Het P is the heterogeneity p-value from the Cochrane Q test, BP vs SCZ p is the p-value from the direct comparison of frequencies between SCZ and BP. PGC BP and PGC SCZ are the association results from the published PGC1 analyses.

Supplementary Table 3. Most significant SNP in 6 genome-wide significant regions from BP+SCZ analysis H e Closest BP SCZ BP control SCZ control t gene SNP Position (hg18) BP vs controls P BP+SCZ OR OR BP MAF MAF MAF MAF P BP vs SCZ P PGC BP 0 . 8 1.7E- CACNA1C rs1006737 chr12:2162951..2290787 7.43E-08 1.12 1.13 0.348 0.347 0.324 0.327 5 0.54 05 0 . 0 1.9E- MHC rs17693963 chr6:27337244..33069339 4.28E-04 0.84 0.88 0.094 0.087 0.101 0.109 6 0.06 03 0 . 5 6.2E- TRANK1 rs9834970 chr3:36817627..36935664 3.90E-07 0.91 0.90 0.482 0.489 0.505 0.511 5 0.12 06 0 . 3 3.3E- MAD1L1 rs10275045 chr7:1834618..2305931 2.08E-04 0.91 0.92 0.413 0.403 0.427 0.431 5 0.28 04 0 . 7 2.7E- PIK3C2A rs4356203 chr11:17023194..17381287 7.36E-05 1.09 1.09 0.429 0.426 0.41 0.409 0 1.00 01 0 . 7 2.0E- IFI44 rs4650608 chr1:78942596..79066403 1.22E-05 0.91 0.91 0.308 0.316 0.327 0.332 6 0.06 05

Supplementary Figure 1a-f. Regional association plots for 6 genome-wide significant regions from BP+SCZ vs controls GWAS (labeled by nearest gene).

Supplementary Figure 2a-b. Single disease Manhattan plots.

Full results (p-value, r2) for leave on out BP vs SCZ polygenic analysis

This table provides p-values (Table 4a) and pseudo R2 (Table 4b) from logistic regression on mania score and BP polygenic score with MDS components as covariates for each site individually and each p-value threshold used to create the risk score. Values in bold are nominally significant (p-value < 0.05).

Supplementary Table 4a. P-values for all thresholds by target sample Scotlan P-value cutoff Dublin GAIN Germany d Sweden Norway UCL US WTCCC 0.0001 2.13E-01 6.15E-05 9.04E-02 1.11E-01 8.04E-04 1.16E-01 1.30E-02 4.45E-02 1.81E-03 0.001 5.87E-01 1.41E-03 1.16E-03 2.46E-02 2.03E-04 5.78E-01 1.83E-02 1.06E-02 3.08E-03 0.01 1.48E-02 1.16E-11 2.00E-04 2.35E-04 4.10E-05 4.29E-02 4.33E-07 2.35E-05 5.52E-08 0.05 9.52E-03 8.71E-16 5.38E-05 8.82E-05 2.57E-05 3.38E-01 7.28E-05 4.63E-05 2.28E-10 0.1 3.65E-03 1.84E-16 2.80E-05 3.65E-05 3.04E-06 1.85E-01 3.60E-05 1.10E-05 8.59E-12 0.2 7.64E-03 1.45E-18 4.92E-07 8.01E-07 3.50E-07 1.65E-01 2.61E-06 1.44E-06 9.79E-13 0.3 1.72E-02 8.12E-18 3.02E-07 6.43E-06 1.27E-06 3.92E-01 7.82E-07 5.79E-07 8.80E-12 0.4 1.05E-02 1.91E-19 3.09E-07 3.37E-06 2.30E-06 4.74E-01 3.06E-07 1.80E-07 4.66E-12 0.5 1.51E-02 2.12E-19 1.67E-07 3.14E-06 2.89E-06 3.88E-01 7.40E-07 2.33E-07 1.10E-12 1 2.06E-02 9.64E-20 2.55E-07 6.11E-06 2.22E-06 3.40E-01 5.22E-07 3.05E-07 1.59E-12

Supplementary Table 4b. Pseudo r2 for all thresholds by target sample Scotlan P-value cutoff Dublin GAIN Germany d Sweden Norway UCL US WTCCC 0.0001 0.005 0.004 0.002 0.003 0.011 0.005 0.008 0.003 0.007 0.001 0.001 0.002 0.009 0.006 0.013 0.001 0.007 0.005 0.006 0.01 0.019 0.011 0.011 0.015 0.016 0.007 0.034 0.014 0.020 0.05 0.022 0.015 0.014 0.017 0.017 0.002 0.021 0.013 0.028 0.1 0.028 0.016 0.015 0.019 0.021 0.003 0.023 0.015 0.032 0.2 0.023 0.019 0.021 0.027 0.025 0.004 0.030 0.019 0.035 0.3 0.019 0.018 0.022 0.022 0.023 0.001 0.033 0.020 0.032 0.4 0.022 0.020 0.022 0.024 0.022 0.001 0.035 0.022 0.033 0.5 0.019 0.019 0.023 0.024 0.021 0.001 0.033 0.021 0.035 1 0.018 0.020 0.022 0.023 0.022 0.002 0.034 0.021 0.034 Full symptom dimensional results from median split analysis

Quantitative manic dimension results by site

Supplementary Table 5. P-values from logistic regression analysis of BP clinical symptoms in SCZ individuals using median split. P-value threshold Mania Depression Positive Symptoms Negative Symptoms <0.0001 0.338 0.520 0.982 0.714 <0.001 0.083 0.159 0.890 0.550 <0.01 0.415 0.873 0.473 0.780 <0.05 0.042 0.813 0.984 0.889 <0.1 0.012 0.886 0.733 0.732 <0.2 0.004 0.948 0.911 0.864 <0.3 0.003 0.883 0.805 0.730 <0.4 0.005 0.928 0.860 0.719 <0.5 0.004 0.966 0.931 0.649 <1 0.005 0.898 0.946 0.711 This table shows the nine sites included in the analysis of the manic dimension in SCZ cases, the instrument used to measure mania in each sample, the total size of the sample, the mean and standard deviation of the manic score, the site specific p-value and effect size and the overall p- value if that site was removed

Supplementary Table 6. Logistic regression of BP polygenic score and quantitative mania score within sample and overall. Sample Instrument # individuals Mean SD P-value Effect P-value with site removed Dublin OPCRIT 168 0.210 0.172 0.173 1.370 5.0E-05 MGS LDPS 2230 0.270 0.163 0.047 1.986 1.3E-04 CATIE PANSS 304 0.224 0.200 0.583 -0.549 6.0E-06 Munich PANSS 428 0.246 0.210 0.054 1.929 1.3E-04 UCL OPCRIT 446 0.269 0.149 0.985 0.018 1.2E-05 UCLA CASH 442 0.251 0.191 0.002 3.122 7.1E-04 Bonn OPCRIT 466 0.258 0.177 0.003 2.939 3.2E-04 Denmark OPCRIT 92 0.263 0.159 0.277 -1.094 1.0E-05 Aberdeen OPCRIT 619 0.264 0.165 0.020 2.334 2.3E-04 Oslo PANSS 202 0.256 0.196 0.928 -0.090 9.8E-06 Cardiff OPCRIT 380 0.273 0.137 0.460 0.740 4.0E-05 All 5777 0.261 0.172 2.5E-05 4.218 Supplementary Table 7. Genome-wide significant hits before and after removing 186 individuals with particularly high BP polygenic score and manic factor score

With 186 samples removed Closest SNP Position (hg18) B BP P SCZ P Het P BP+SCZ P BP P SCZ P gene P CACNA1C rs1006737 chr12:2162951..2290787 5 7.43E-08 1.65E-06 0.85 8.50E-13 7.43E-08 2.48E-06 MHC rs17693963 chr6:27337244..33069339 3. 4.28E-04 3.27E-09 0.06 5.08E-11 0.0004275 4.84E-09 TRANK1 rs9834970 chr3:36817627..36935664 1. 3.90E-07 7.18E-05 0.55 1.26E-10 3.90E-07 6.65E-05 MAD1L1 rs10275045 chr7:1834618..2305931 2. 2.08E-04 1.84E-06 0.35 3.02E-09 0.0002078 2.56E-06 PIK3C2A* rs4356203 chr11:17023194..17381287 6. 7.36E-05 2.14E-05 0.7 4.46E-09 7.36E-05 1.40E-05 IFI44L rs4650608 chr1:78942596..79066403 8. 1.22E-05 1.77E-04 0.76 1.03E-08 1.22E-05 2.21E-04 .

Supplementary Figure 3. Odds ratios of 22 previously identified genome-wide significant hits both before (red) and after (blue) removing 186 individuals with particularly high BP polygenic score and manic factor score. Supplementary Figure 4. Average pseudo R2 values for polygenic prediction of BP vs SCZ phenotype into the target sample where all other samples were used for discovery with 186 samples removed Authors and Affiliations PGC First name Last name Affiliation Country Workgroup(s)

HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, BP Devin Absher USA USA. KG Jebsen Centre for Psychosis Research, Institute of Clinical SCZ Ingrid Agartz Medicine; University of Oslo; Department of Research; Norway Diakonhjemmet Hospital; Oslo; Norway Molecular and Behavioral Neuroscience Institute, University of BP Huda Akil USA Michigan, Ann Arbor, Michigan, USA. Department of Psychiatry and Behavioral Sciences; Emory SCZ Farooq Amin University and Atlanta Veterans Affairs Medical Center; Atlanta; USA Georgia; USA KG Jebsen Centre for Psychosis Research; Institute of Clinical SCZ, BP Ole A Andreassen Medicine; University of Oslo; Division of Mental Health and Norway Addiction, Oslo University Hospital, Oslo, Norway Molecular Psychiatry Laboratory, Mental Health Sciences Unit, BP Adebayo Anjorin UK University College London, London, UK.

SCZ Maria H. Azevedo Faculty of Medicine, University of Coimbra, Coimbra, Portugal Portugal

Department of Clinical Neuroscience, Karolinska Institutet, BP Lena Backlund Sweden Stockholm, Sweden.

Department of Psychiatry, University of Chicago, Chicago, Illinois, BP Judith A Badner USA USA.

Department of Psychiatry, Weill Medical College, Cornell BP Jack D Barchas USA University, New York, New York, USA.

BP Thomas B Barrett Portland Veterans Affairs Medical Center, Portland, Oregon, USA. USA

Molecular Psychiatry Laboratory; Research Department of Mental SCZ, BP Nicholas Bass Health Sciences; University College London Medical School; UK Windeyer Institute of Medical Sciences; London; England; UK Department of Psychiatry and Psychotherapy; ENBREC Group; BP Michael Bauer Germany University Hospital Carl Gustav Carus; Dresden; Germany. INSERM, U955, Psychiatrie Génétique, Créteil, France.; Université Paris Est, Faculté de Médecine, Créteil, France.; Assistance BP Frank Bellivier Publique–Hopitaux de Paris (AP -HP); Hopital H. Mondor–A. France Chenevier; Département de Psychiatrie; Créteil; France.; ENBREC group; Fondation Fondamental; Créteil; France. Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, BP Sarah E Bergen Boston, Massachusetts, USA; Stanley Center for Psychiatric USA Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Department of Psychiatry, University of Pennsylvania, BP Wade Berrettini USA Philadelphia, Pennsylvania, USA.

Department of Psychiatry; University of Iowa Carver College of SCZ Donald W Black USA Medicine; Iowa City; Iowa; USA

Division of Psychiatry; University of Edinburgh; Royal Edinburgh SCZ, BP Douglas H R Blackwood UK Hospital; Edinburgh; Scotland; UK

The Scripps Translational Science Institute and Scripps Health, La BP Cinnamon S Bloss USA Jolla, California, USA. Department of Biostatistics and Center for Statistical Genetics, BP Michael Boehnke School of Public Health, University of Michigan, Ann Arbor, USA Michigan, USA. Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King’s College London, De Crespigny Park BP Gerome Breen UK Denmark Hill, London, UK.; University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, UK. Department of Genetic Epidemiology in Psychiatry; Central BP René Breuer Institute of Mental Health; University of Heidelberg; Mannheim; Germany Germany School of Nursing; Louisiana State University Health Sciences SCZ Nancy G Buccola USA Center; New Orleans; Louisiana; USA

Department of Psychiatry and Human Behavior, University of BP William E Bunney USA California, Irvine, California, USA. Department of Human Genetics, Department of Psychiatry, BP Margit Burmeister Molecular and Behavioral Neuroscience Institute, University of USA Michigan, Ann Arbor, Michigan, USA. Department of Psychiatry; University of California at San Francisco BP, SCZ William Byerley and NCIRE (Northern California Institute for Research And USA Education); San Francisco; California; USA Department of Psychiatry, School of Clinical and Experimental BP Sian Caesar UK Medicine, Birmingham University, Birmingham, UK. UCLA Center for Neurobehavioral Genetics; University of California at Los Angeles; Department of Human Genetics; SCZ Rita M Cantor USA University of California at Los Angeles; Los Angeles; California; USA Stanley Center for Psychiatric Research, Broad Institute of MIT BP Kim Chambert USA and Harvard, Cambridge, Massachusetts, USA.

SCZ Khalid Choudhury University College London UK

(1) Dept. of Genomics; Life & Brain Center; University of Bonn; Bonn; (2) Institute of Neuroscience and Medicine (INM -1); BP, SCZ Sven Cichon Germany Research Center Juelich; Juelich; (3) Institute of Human Genetics; Unviersity of Bonn; Bonn; Germany

SCZ C. Robert Cloninger Washington University USA

Social; Genetic and Developmental Psychiatry Centre; Institute of BP David A Collier UK Psychiatry; King's College; London; England; UK Neuropsychiatric Genetics Research Group; Department of BP, SCZ Aiden Corvin Psychiatry and Institute of Molecular Medicine; Trinity College Ireland Dublin; Dublin; Ireland

BP William H Coryell University of Iowa USA

BP, SCZ Nicholas Craddock Cardiff University School of Medicine UK The Translational Genomics Research Institute, Phoenix, Arizona, BP David W Craig USA USA.

SCZ David Curtis East London NHS Foundation Trust/QMUL UK

Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, Analysis, BP, SCZ Mark Daly USA USA.; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

SCZ Susmita Datta University College London UK

Division of Neuroscience, Medical Research Institute, University of BP Richard Day IL Dundee, Ninewells Hospital & Medical School, Dundee, UK. (1) Dept. of Genomics; Life & Brain Center; University of Bonn; BP Franziska A Degenhardt Bonn; (2) Institute of Human Genetics; Unviersity of Bonn; Bonn; Germany Germany KG Jebsen Centre for Psychosis Research, Institute of Clinical BP, SCZ Srdjan Djurovic Medicine, University of Oslo, Oslo, Norway.; Department of Norway Medical Genetics, Oslo University Hospital, Oslo, Norway. Department of Psychiatry and Behavioral Sciences; NorthShore SCZ Jubao Duan University HealthSystem and University of Chicago; Evanston; USA Illinois; USA Department of Non -communicable Disease Epidemiology; BP, SCZ Frank Dudbridge London School of Hygiene and Tropical Medicine; London; UK England; UK Department of Biochemistry and Molecular Biology, Department of Medical and Molecular Genetics, Indiana University School of BP Howard J Edenberg Jr. Medicine, Indianapolis, Indiana, USA.; Department of Medical and USA Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. Social, Genetic and Developmental Psychiatry (SGDP) Centre, The BP Amanda Elkin Institute of Psychiatry, King’s College London, De Crespigny Park UK Denmark Hill, London, UK. INSERM, U955, Psychiatrie Génétique, Créteil, France.; Université Paris Est, Faculté de Médecine, Créteil, France.; Assistance BP Bruno Etain Publique–Hopitaux de Paris (AP -HP); Hopital H. Mondor–A. France Chenevier; Département de Psychiatrie; Créteil; France.; ENBREC group; Fondation Fondamental; Créteil; France. Washington VA Medical Center; Department of Psychiatry; Georgetown University School of Medicine; Washington; DC; USA; SCZ Ayman Fanous USA Department of Psychiatry; Virginia Commonwealth University School of Medicine; Richmond; Virginia; USA Social, Genetic and Developmental Psychiatry (SGDP) Centre, The BP Anne E Farmer Institute of Psychiatry, King’s College London, De Crespigny Park UK Denmark Hill, London, UK.

BP Manuel A Ferreira Queensland Institute of Medical Research, Brisbane, Australia. Australia

Division of Neuroscience, Medical Research Institute, University of BP I Nicol Ferrier UK Dundee, Ninewells Hospital & Medical School, Dundee, UK. Department of Biostatistics and Center for Statistical Genetics, BP Matthew Flickinger School of Public Health, University of Michigan, Ann Arbor, USA Michigan, USA. Department of Medical and Molecular Genetics, Indiana BP Tatiana Foroud USA University School of Medicine, Indianapolis, Indiana, USA. Department of Genetic Epidemiology in Psychiatry; Central BP Josef Frank Institute of Mental Health; University of Heidelberg; Mannheim; Germany Germany Medical Research Council (MRC) Centre for Neuropsychiatric BP Christine Fraser Genetics and Genomics, Henry Wellcome Building, School of UK Medicine, Cardiff University, Heath Park, Cardiff, UK. Department of Psychiatry; University of Colorado Denver; Aurora; SCZ Robert Freedman USA Colorado; USA

UCLA Center for Neurobehavioral Genetics; University of SCZ Nelson B Freimer USA California at Los Angeles; Los Angeles; California; USA

Molecular and Clinical Neurobiology; Department of Psychiatry; SCZ Marion Friedl Germany Ludwig - Maximilians -University; Munich; Germany

Department of Molecular Medicine, Karolinska Institutet, BP Louise Frisén Sweden Stockholm, Sweden. Prince of Wales Medical Institute; Sydney; Australia.; University of BP Janice Fullerton Australia New South Wales; Sydney; Australia. Department of Psychiatry and Behavioral Sciences; NorthShore SCZ Pablo V Gejman University HealthSystem and University of Chicago; Evanston; USA Illinois; USA MRC Centre for Neuropsychiatric Genetics and Genomics; SCZ Lyudmila Georgieva Department of Psychological Medicine and Neurology; School of UK Medicine; Cardiff University; Cardiff; Wales; UK Institute for Medical Biometry, Informatics and Epidemiology, BP Elliot S Gershon Germany University of Bonn, Bonn, Germany.

Molecular and Clinical Neurobiology; Department of Psychiatry; SCZ Ina Giegling Germany Ludwig - Maximilians -University; Munich; Germany Neuropsychiatric Genetics Research Group, Department of BP, SCZ Michael Gill Psychiatry and Institute of Molecular Medicine, Trinity College Ireland Dublin, Dublin, Ireland. Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of BP Katherine Gordon -Smith Medicine, Cardiff University, Heath Park, Cardiff, UK.; Department UK of Psychiatry, School of Clinical and Experimental Medicine, Birmingham University, Birmingham, UK. Medical Research Council (MRC) Centre for Neuropsychiatric BP Elaine K Green Genetics and Genomics, Henry Wellcome Building, School of UK Medicine, Cardiff University, Heath Park, Cardiff, UK. Neurosciences Centre of Excellence in Drug Discovery, BP Tiffany A Greenwood Italy GlaxoSmithKline Research and Development, Verona, Italy.

SCZ The Genetic Risk Outcome of Psychosis (GROUP) Consortium Medical Research Council (MRC) Centre for Neuropsychiatric BP Detelina Grozeva Genetics and Genomics, Henry Wellcome Building, School of UK Medicine, Cardiff University, Heath Park, Cardiff, UK. Department of Biostatistics and Center for Statistical Genetics, BP Weihua Guan School of Public Health, University of Michigan, Ann Arbor, USA Michigan, USA. Molecular Psychiatry Laboratory; Research Department of Mental BP, SCZ Hugh Gurling Health Sciences; University College London Medical School; UK Windeyer Institute of Medical Sciences; London; England; UK

BP Omar Gustafsson deCODE Genetics, Sturlugata 8 101 Reykjavik, Iceland. Iceland

Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of BP, SCZ Marian L Hamshere Medicine, Cardiff University, Heath Park, Cardiff, UK.; Biostatistics UK and Bioinformatics Unit, Cardiff University School of Medicine, Cardiff, UK. SCZ Thomas F Hansen Institute of Biological Psychiatry; MHC Sct. Hans; Copenhagen Denmark University Hospital; Roskilde; Denmark

Molecular and Clinical Neurobiology; Department of Psychiatry; SCZ Annette M Hartmann Germany Ludwig - Maximilians -University; Munich; Germany

Department of Clinical and Developmental Psychology; Institute BP Martin Hautzinger Germany of Psychology; University of Tubingen; Tubingen; Germany. INSERM, U955, Psychiatrie Génétique; Université Paris Est, Faculté de Médecine; Assistance Publique–Hôpitaux de Paris (AP -HP), BP Chantal Henry Hôpital H. Mondor–A. Chenevier, Département de Psychiatrie; ENBREC group, Fondation Fondamental, Créteil, France.

Dept. of Genomics; Life & Brain Center; University of Bonn; Bonn; BP Stefan Herms Germany Germany

Department of Psychiatry and Behavioral Sciences, Howard BP Maria Hipolito USA University College of Medicine, Washington, DC, USA. Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of BP, SCZ Peter A Holmans Medicine, Cardiff University, Heath Park, Cardiff, UK.; Biostatistics UK and Bioinformatics Unit, Cardiff University School of Medicine, Cardiff, UK. Department of Medical Epidemiology and Biostatistics; Karolinska BP, SCZ Christina M Hultman Sweden Institutet; Stockholm; Sweden

Institute of Biological Psychiatry; MHC Sct. Hans; Copenhagen SCZ Andrés Ingason Denmark University Hospital; Roskilde; Denmark

Inserm U955, Psychiatrie Génétique, Fondation FondaMental, BP Stephane Jamain France Creteil, France

Department of Psychiatry and Behavioral Sciences, Center for BP Edward G Jones USA Neuroscience, University of California, Davis, California, USA.

Department of Psychiatry, School of Clinical and Experimental BP Lisa Jones UK Medicine, Birmingham University, Birmingham, UK. Medical Research Council (MRC) Centre for Neuropsychiatric BP Ian R Jones Genetics and Genomics, Henry Wellcome Building, School of UK Medicine, Cardiff University, Heath Park, Cardiff, UK.

SCZ Anna Kahler Karolinska Institutet Sweden

Département de Psychiatrie et de Psychologie clinique, CHU de Nancy, Hôpital Jeanne-d’Arc, Toul, 54200, France; Fondation BP Jean-Pierre Kahn France Fondamental, Créteil, France.

Molecular Psychiatry Laboratory, Mental Health Sciences Unit, BP Radhika Kandaswamy UK University College London, London, UK.

Department of Psychology; University of Colorado; Boulder; SCZ Matthew C Keller USA Boulder; Colorado; USA Department of Psychiatry, University of California San Diego, La Jolla, California, USA.; Department of Psychiatry; Special BP John R Kelsoe USA Treatment and Evaluation Program (STEP); Veterans Affairs San Diego Healthcare System; San Diego; California; USA. Virginia Institute for Psychiatric and Behavioral Genetics; Departments of Psychiatry and Human and Molecular Genetics; SCZ Kenneth Kendler USA Virginia Commonwealth University School of Medicine; Richmond; Virginia; USA BP James L Kennedy Psychiatric Neurogenetics Section, Centre for Addiction and Canada Mental Health, Toronto, Ontario, Canada. Neuropsychiatric Genetics Research Group, Dept of Psychiatry SCZ Elaine Kenny and Institute of Molecular Medicine, Trinity College Dublin, Ireland Dublin, Ireland Department of Genetics; University of North Carolina at Chapel SCZ Yunjung Kim USA Hill; Chapel Hill; North Carolina; USA MRC Centre for Neuropsychiatric Genetics and Genomics; BP, SCZ George Kirov Department of Psychological Medicine and Neurology; School of UK Medicine; Cardiff University; Cardiff; Wales; UK Department of Medical and Molecular Genetics, Indiana BP Daniel L Koller USA University School of Medicine, Indianapolis, Indiana, USA.

Molecular and Clinical Neurobiology; Department of Psychiatry; SCZ Bettina Konte Germany Ludwig - Maximilians -University; Munich; Germany

SCZ Robert Krasucki University College London UK

Department of Biostatistics and Center for Statistical Genetics, BP Phoenix Kwan School of Public Health, University of Michigan, Ann Arbor, USA Michigan, USA. Department of Medical Epidemiology and Biostatistics, Karolinska BP Mikael Landén Institutet, Stockholm, Sweden.; Institute of Neuroscience and Sweden Physiology, University of Gothenburg, Gothenburg, Sweden. Institute of Neuroscience and Physiology, University of BP Niklas Langstrom Sweden Gothenburg, Gothenburg, Sweden.

BP Mark Lathrop Centre National de Génotypage; Evry; France. France

Molecular Psychiatry Laboratory; Research Department of Mental BP, SCZ Jacob Lawrence Health Sciences; University College London Medical School; UK Windeyer Institute of Medical Sciences; London; England; UK Department of Psychiatry and Behavioral Sciences, Howard BP William B Lawson USA University College of Medicine, Washington, DC, USA. INSERM, U955, Psychiatrie Génétique, Créteil, France.; Université Paris Est, Faculté de Médecine, Créteil, France.; Assistance BP Marion Leboyer Publique–Hopitaux de Paris (AP -HP); Hopital H. Mondor–A. France Chenevier; Département de Psychiatrie; Créteil; France.; ENBREC group; Fondation Fondamental; Créteil; France. Psychiatric and Neurodevelopmental Genetics Unit, Analysis, BP, SCZ Phil Hyoun Lee USA Massachusetts General Hospital; Boston, MA Department of Psychiatry; Division of Research; The Zucker Hillside Hospital Division of the North Shore - Long Island Jewish Health System; Glen Oaks; New York; USA; Center for Psychiatric SCZ Todd Lencz Neuroscience; The Feinstein Institute for Medical Research; USA Manhasset; New York; USA; Department of Psychiatry and Behavioral Science; Albert Einstein College of Medicine of Yeshiva University; Bronx; New York; USA Department of Psychiatry and Behavioral Sciences; Stanford SCZ Douglas F Levinson USA University; Stanford; California; USA

Department of Human Genetics, University of Michigan, Ann BP Jun Li USA Arbor, Michigan, USA

Department of Medical Epidemiology and Biostatistics; Karolinska BP Paul Lichtenstein Sweden Institutet; Stockholm; Sweden

Department of Psychiatry; Columbia University; New York; New SCZ Jeffrey A Lieberman USA York; USA Department of Biostatistics, University of North Carolina, Chapel BP, SCZ Danyu Lin USA Hill, North Carolina, USA.

Department of Psychiatry, University of Chicago, Chicago, Illinois, BP Chunyu Liu USA USA.

Department of Psychiatry, University of Pennsylvania, BP Falk W Lohoff USA Philadelphia, Pennsylvania, USA.

BP Susanne Lucae Max Planck Institute of Psychiatry Germany

SCZ Patrik Magnusson Karolinska Institutet Sweden

Department of Mental Health, Johns Hopkins University and BP Pamela B Mahon USA Hospital, Baltimore, Maryland, USA.

BP; SCZ Wolfgang Maier Dept. of Psychiatry; University of Bonn; Bonn; Germany Germany

Department of Psychiatry; Division of Research; The Zucker Hillside Hospital Division of the North Shore - Long Island Jewish Health System; Glen Oaks; New York; USA; Center for Psychiatric SCZ Anil K Malhotra Neuroscience; The Feinstein Institute for Medical Research; USA Manhasset; New York; USA; Department of Psychiatry and Behavioral Science; Albert Einstein College of Medicine of Yeshiva University; Bronx; New York; USA

BP Nicholas G Martin Queensland Institute of Medical Research, Brisbane, Australia. Australia

(1) Dept. of Genomics; Life & Brain Center; University of Bonn; Bonn; Germany; (2) Department of Biostatistics; Harvard School of BP; SCZ Manuel Mattheisen Germany Public Health; Boston; MA; USA; (3) Institute for Genomic Mathematics; University of Bonn; Bonn; Germany Division of Neuroscience, Medical Research Institute, University of BP Keith Matthews UK Dundee, Ninewells Hospital & Medical School, Dundee, UK. KG Jebsen Centre for Psychosis Research, Institute of Clinical BP, SCZ Morten Mattingsdal Medicine, University of Oslo, Oslo, Norway.; Sorlandet Hospital Norway HF, Kristiansand, Norway.

SCZ Steve McCarroll Harvard/Broad Institute USA

Division of Psychiatry; University of Edinburgh; Royal Edinburgh BP Kevin A McGhee UK Hospital; Edinburgh; Scotland; UK Social, Genetic and Developmental Psychiatry (SGDP) Centre, The BP Peter McGuffin Institute of Psychiatry, King’s College London, De Crespigny Park UK Denmark Hill, London, UK. Department of Psychiatry, University of Michigan, Ann Arbor, BP Melvin G McInnis USA Michigan, USA. Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.; Medical Genetics Section, University of BP, SCZ Andrew McIntosh UK Edinburgh Molecular Medicine Centre, Western General Hospital, Edinburgh, UK. Neurosciences Centre of Excellence in Drug Discovery, BP Rebecca McKinney Italy GlaxoSmithKline Research and Development, Verona, Italy. Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.; Medical Genetics Section, University of BP Alan W McLean UK Edinburgh Molecular Medicine Centre, Western General Hospital, Edinburgh, UK. National Institute of Mental Health, US National Institutes of BP Francis J McMahon USA Health, Bethesda, Maryland, USA. Molecular Psychiatry Laboratory; Research Department of Mental BP, SCZ Andrew McQuillin Health Sciences; University College London Medical School; UK Windeyer Institute of Medical Sciences; London; England; UK Keck School of Medicine, University of Southern California, Los SCZ Helena Medeiros, MSW USA Angeles, California, USA

Analysis Sarah E Medland Queensland Institute of Medical Research, Brisbane Australia

Department of Genetic Epidemiology in Psychiatry, Central BP Sandra Meier Institute of Mental Health Mannheim, University of Heidelberg, Germany Mannheim, Germany. KG Jebsen Centre for Psychosis Research; Institute of Clinical BP, SCZ Ingrid Melle Medicine; University of Oslo; Division of Mental Health and Norway Addiction, Oslo University Hospital, Oslo, Norway Molecular and Behavioral Neuroscience Institute, University of BP Fan Meng USA Michigan, Ann Arbor, Michigan, USA.

Department of Psychiatry; First Psychiatric Clinic; Alexander SCZ Vihra Milanova Bulgaria University Hospital; Sofia; Bulgaria

School of Psychiatry; University of New South Wales and Black BP Philip B Mitchell Austrailia Dog Institute; Sydney; New South Wales; Australia.

BP Grant W Montgomery Queensland Institute of Medical Research, Brisbane, Australia. Austrailia

Stanley Center for Psychiatric Research, Broad Institute of MIT BP Jennifer Moran USA and Harvard, Cambridge, Massachusetts, USA. Department of Psychiatry, St. Olavs Hospital, Trondheim, BP Gunnar Morken Norway.; Department of Neuroscience, Norwegian University of Norway Science and Technology, Trondheim, Norway. Neuropsychiatric Genetics Research Group; Department of BP, SCZ Derek W Morris Psychiatry and Institute of Molecular Medicine; Trinity College Ireland Dublin; Dublin; Ireland Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of BP, SCZ Valentina Moskvina Medicine, Cardiff University, Heath Park, Cardiff, UK.; Biostatistics UK and Bioinformatics Unit, Cardiff University School of Medicine, Cardiff, UK. Queensland Brain Institute and Queensland Centre for Mental SCZ Bryan J Mowry Health Research; University of Queensland; Brisbane; Australia Queensland; Australia Neurosciences Centre of Excellence in Drug Discovery, BP Pierandrea Muglia Italy GlaxoSmithKline Research and Development, Verona, Italy. Institute of Human Genetics, University of Bonn, Bonn, Germany.; BP Thomas W Muhleisen German Center for Neurodegenerative Disorders (DZNE), Bonn, Germany Germany. Division of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.; Medical Genetics Section, University of BP Walter J Muir UK Edinburgh Molecular Medicine Centre, Western General Hospital, Edinburgh, UK.

BP Bertram Muller -Myhsok Max Planck Institute of Psychiatry; Munich Germany

HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, BP Richard M Myers USA USA.

Analysis, SCZ Benjamin Neale Massachusetts General Hospital/Broad Institute USA Virginia Institute for Psychiatric and Behavioral Genetics, Virginia Analysis Michael C. Neale USA Commonwealth University

Neurosciences Centre of Excellence in Drug Discovery, BP Caroline M Nievergelt Italy GlaxoSmithKline Research and Development, Verona, Italy. MRC Centre for Neuropsychiatric Genetics and Genomics; BP Ivan Nikolov Department of Psychological Medicine and Neurology; School of UK Medicine; Cardiff University; Cardiff; Wales; UK Department of Psychiatry, WPIC BP Vishwajit Nimgaonkar University of Pittsburgh School of Medicine.Pittsburgh, USA Pennsylvania, USA. (1) Dept. of Genomics; Life & Brain Center; University of Bonn; Bonn; (2) Institute of Human Genetics; Unviersity of Bonn; Bonn; BP; SCZ Markus M Nothen Germany Germany; (3) German Center for Neurodegenerative Disorders (DZNE); Bonn; Germany Department of Medical and Molecular Genetics, Indiana BP John I Nurnberger University School of Medicine, Indianapolis, Indiana, USA. USA

Department of Psychiatry and Behavioral Sciences, Howard BP Evaristus A Nwulia USA University College of Medicine, Washington, DC, USA. MRC Centre for Neuropsychiatric Genetics and Genomics; BP, SCZ Michael C O'Donovan Department of Psychological Medicine and Neurology; School of UK Medicine; Cardiff University; Cardiff; Wales; UK Stanley Center for Psychiatric Research, Broad Institute of MIT BP, SCZ Colm O'Dushlaine USA and Harvard, Cambridge, Massachusetts, USA.

Department of Psychiatry; University of Colorado Denver; Aurora; SCZ Ann Olincy USA Colorado; USA

Institute of Biological Psychiatry; MHC Sct. Hans; Copenhagen SCZ Line Olsen Denmark University Hospital; Roskilde; Denmark Department of Medical Genetics and Rudolf Magnus Institute of Neuroscience; University Medical Center Utrecht; Utrecht; The The Netherlands; UCLA Center for Neurobehavioral Genetics; SCZ Roel A Ophoff Netherland University of California at Los Angeles; Department of Human s; USA Genetics; University of California at Los Angeles; Los Angeles; California; USA Department of Molecular Medicine, Karolinska Institutet, BP Urban Osby Sweden Stockholm, Sweden.

BP Hogni Oskarsson Therapeia; Reykjavik; Iceland. Iceland

MRC Centre for Neuropsychiatric Genetics and Genomics; BP, SCZ Michael J Owen Department of Psychological Medicine and Neurology; School of UK Medicine; Cardiff University; Cardiff; Wales; UK Keck School of Medicine; University of Southern California; Los SCZ Michele T Pato USA Angeles; California; USA

Keck School of Medicine; University of Southern California; Los SCZ Carlos N Pato USA Angeles; California; USA Psychiatric and Neurodevelopmental Genetics Unit, BP Roy H Perlis Massachusetts General Hospital; Stanley Center for Psychiatric USA Research, Broad Institute, Boston, MA Department of Psychiatry; National University Hospital; Reykjavik; BP Hannes Petursson Iceland Iceland BP, SCZ Benjamin S Pickard Division of Psychiatry, University of Edinburgh, Royal Edinburgh UK Hospital, Edinburgh, UK.; Medical Genetics Section, University of Edinburgh Molecular Medicine Centre, Western General Hospital, Edinburgh, UK.

SCZ Jonathan Pimm University College London UK

BP Porgeir Porgeirsson deCODE Genetics, Sturlugata 8 101 Reykjavik, Iceland. Iceland

VU University; Center for Neurogenomics and Cognitive Research The SCZ Danielle Posthuma (CNCR); Department of Functional Genomics; VU Medical Centre; Netherland Department of Medical Genomics; Amsterdam; The Netherlands s

BP James B Potash University of Iowa USA

BP Peter Propping Institute of Human Genetics, University of Bonn, Bonn, Germany. Germany

Division of Psychiatric Genomics, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA.; Analytic and Translational Genetics Unit, Massachusetts General Analysis, BP, SCZ Shaun M Purcell USA Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.

SCZ Vinay Puri University College London UK

SCZ Digby Quested University of Oxford UK

Neuropsychiatric Genetics Research Group; Department of BP Emma M Quinn Psychiatry and Institute of Molecular Medicine; Trinity College Ireland Dublin; Dublin; Ireland Institute of Biological Psychiatry, Sct. Hans Mental Health Center (MHS); Department of Clinical Medicine, University of SCZ Henrik B Rasmussen DK Copenhagen; The Lundbeck Initiative for Integrative Psychiatric Research, iPSYCH; Denmark Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, BP Soumya Raychaudhuri USA USA.; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Department of Psychiatry; Psychosomatics and Psychotherapy; BP Andreas Reif Germany University of Wuerzburg

Washington University School of Medicine, St. Louis, Missouri, BP John Rice USA USA.

Central Institute of Mental Health, Medical Faculty Mannheim, SCZ, BP Marcella Rietschel Germany Univ. of Heidelberg J5, 68159 Mannheim, Germany Depts. of Psychiatry and Human & Molecular Genetics, Virginia SCZ Brien Riley Institute of Psychiatric and Behavioral Genetics, Virginia USA Commonwealth University, Richmond VA Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, Analysis, SCZ, BP Stephan Ripke USA USA.; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Analytic and Translational Genetics Unit, Massachusetts General SCZ Lizzy Rossin Hospital and Harvard Medical School, Boston, Massachusetts, USA USA. Division of Psychiatric Genomics, Department of Psychiatry, BP, SCZ Douglas M Ruderfer USA Mount Sinai School of Medicine, New York, New York, USA.

SCZ Dan Rujescu Molecular and Clinical Neurobiology; Department of Psychiatry; Germany Ludwig - Maximilians -University; Munich; Germany Department of Psychiatry and Behavioral Sciences; NorthShore SCZ Alan R Sanders University HealthSystem and University of Chicago; Evanston; USA Illinois; USA Department of Molecular Medicine, Karolinska Institutet, BP Martin Schalling Sweden Stockholm, Sweden.

Psychiatry and Behavioral Science, Stanford University School of BP Alan F Schatzberg USA Medicine, Palo Alto, California, USA.

BP William A Scheftner Rush University Medical Center USA

Prince of Wales Medical Institute; Sydney; Australia.; University of BP Peter R Schofield Austrailia New South Wales; Sydney; Australia.

The Scripps Translational Science Institute and The Scripps BP Nicholas J Schork USA Research Institute, La Jolla, California, USA. (1) Department of Psychiatry & Psychotherapy; University of 1) SCZ, BP Thomas G Schulze Gottingen; Gottingen; (2) Department of Psychiatry & Behavioral Germany; Sciences; Johns Hopkins University; Baltimore; MD 2) USA

BP Johannes Schumacher Institute of Human Genetics, University of Bonn, Bonn, Germany. Germany

BP Markus Schwarz Psychiatric Center Nordbaden; Wiesloch; Germany. Germany

Stanley Center for Psychiatric Research, Broad Institute of MIT BP Edward Scolnick USA and Harvard, Cambridge, Massachusetts, USA. Department of Biostatistics and Center for Statistical Genetics, BP Laura J Scott School of Public Health, University of Michigan, Ann Arbor, USA Michigan, USA. Division of Cancer Epidemiology and Genetics; National Cancer SCZ Jianxin Shi USA Institute; Bethesda; Maryland; USA

Neurosciences Centre of Excellence in Drug Discovery, BP Paul D Shilling Italy GlaxoSmithKline Research and Development, Verona, Italy.

Department of Psychiatry; National University Hospital; BP Engilbert Sigurdsson Iceland Department of Psychiatry; University of Iceland; Reykjavik; Iceland

Mount Sinai School of Medicine / Bronx Veterans Affairs Medical SCZ Jeremy M. Silverman USA Center

Division of Psychiatric Genomics, Department of Psychiatry, BP, SCZ Pamela Sklar USA Mount Sinai School of Medicine, New York, New York, USA.

The Scripps Translational Science Institute and Scripps Health, La BP Erin N Smith USA Jolla, California, USA.

Institute of Medical Sciences; University of Aberdeen; Foresterhill; BP, SCZ David St. Clair UK Aberdeen; Scotland; UK

BP Kari Stefansson deCODE Genetics, Sturlugata 8 101 Reykjavik, Iceland. Iceland

BP Hreinn Stefansson deCODE genetics; Reykjavik; Iceland Iceland

Psychiatric and Neurodevelopmental Genetics Unit, BP Jordan W Smoller Massachusetts General Hospital; Stanley Center for Psychiatric USA Research, Broad Institute, Boston, MA Institute of Medical Biometry; Informatics and Epidemiology BP Michael Steffens Germany (IMBIE); University of Bonn; Bonn; Germany

BP Stacy Steinberg deCODE genetics; Reykjavik; Iceland Iceland

Social, Genetic and Developmental Psychiatry (SGDP) Centre, The BP John Strauss Institute of Psychiatry, King’s College London, De Crespigny Park UK Denmark Hill, London, UK. Department of Genetic Epidemiology in Psychiatry, Central BP Jana Strohmaier Institute of Mental Health Mannheim, University of Heidelberg, Germany Mannheim, Germany. Department of Psychiatry; Columbia University; New York; New SCZ T Scott Stroup USA York; USA

SCZ Patrick F Sullivan University of North Carolina at Chapel Hill USA

The Translational Genomics Research Institute, Phoenix, Arizona, BP Szabocls Szelinger USA USA.

SCZ Srinivasa Thirumalai West Berkshire NHS Trust/University College London UK

Molecular and Behavioral Neuroscience Institute, University of BP Robert C Thompson USA Michigan, Ann Arbor, Michigan, USA.

BP Federica Tozzi GlaxoSmithKline Italy

Department of Genetic Epidemiology in Psychiatry; Central BP Jens Treutlein Institute of Mental Health; University of Heidelberg; Mannheim; Germany Germany Molecular Neuropsychiatry and Development Laboratory, Centre BP John B Vincent Canada for Addiction and Mental Health, Toronto, Ontario, Canada.

The University of Queensland, Queensland Brain Institute & SCZ Peter M Visscher Australia UnivDiamantina Institute, Brisbane, Australia

Molecular and Behavioral Neuroscience Institute, University of BP Stanley J Watson USA Michigan, Ann Arbor, Michigan, USA.

Institute of Biological Psychiatry; MHC Sct. Hans; Copenhagen SCZ Thomas Werge Denmark University Hospital; Roskilde; Denmark

Institute for Medical Biometry, Informatics and Epidemiology, BP Thomas F Wienker Germany University of Bonn, Bonn, Germany. Social, Genetic and Developmental Psychiatry (SGDP) Centre, The BP Richard Williamson Institute of Psychiatry, King’s College London, De Crespigny Park UK Denmark Hill, London, UK. Department of Genetic Epidemiology in Psychiatry, Central BP Stephanie H Witt Institute of Mental Health Mannheim, University of Heidelberg, Germany Mannheim, Germany. School of Psychiatry; University of New South Wales and Black BP Adam Wright Austrailia Dog Institute; Sydney; New South Wales; Australia.

Dalla Lana School of Public Health, University of Toronto, Toronto, BP Wei Xu Canada Canada. Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.; BP Allan H Young UK: Canada University of British Columbia (UBC) Institute of Mental Health, Vancouver, British Columbia, Canada. MRC Centre for Neuropsychiatric Genetics and Genomics; SCZ Stan Zammit Department of Psychological Medicine and Neurology; School of UK Medicine; Cardiff University; Cardiff; Wales; UK Department of Mental Health, Johns Hopkins University and BP Peter P Zandi USA Hospital, Baltimore, Maryland, USA. Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, BP Peng Zhang USA Michigan, USA.; Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA. Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, BP Sebastian Zollner USA Michigan, USA.; Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA.